Ekso Bionics�� EksoGT Exoskeleton Adopted in Singapore for Groundbreaking Clinical Study

RICHMOND, CA�- Media OutReach - May 6, 2019 – Ekso Bionics Holdings,
Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical
and industrial use, today announced that the National University Health System
(NUHS) in Singapore has adopted three EksoGT exoskeletons for a groundbreaking
clinical study. NUHS is one of the first national health systems in Asia to
study how advanced exoskeleton technology can improve mobility and
rehabilitation outcomes, and the first to study it across
the entire continuum of care.

Photograph courtesy of Ekso Bionics

 

The Improving
Mobility via Exoskeletons (iMOVE) program, supported by
Temasek Foundation and Trailblazer Foundation Limited, will study patient
outcomes and assess the viability and potential for scaling-up the use of
robotic exoskeletons across the continuum of rehabilitation care from hospital
to community.  The study will focus on patients
suffering from stroke and spinal cord injuries, especially for the elderly.  The three EksoGT devices will be used at
multiple NUHS partner sites including Alexandra Hospital, NTUC Health, St
Luke’s Eldercare, St Luke’s Hospital, and Stroke Support Station.

The iMOVE program was inaugurated today by Mr. Chan Heng Kee, Permanent
Secretary of Ministry of Health, together with Professor John Wong Eu Li, Chief
Executive of National University Hospital System and Mr. Richard Magnus,
Chairman of Temasek Foundation. 

 

“We are delighted to be part of a program that
will facilitate greater treatment accessibility in Singapore. Globally 15 million people suffer from a stroke every year; Asia is
more than half the world’s population with a rapidly aging population in many
countries.  With aging, mobility becomes
a big challenge.  The core mission of Ekso is to help people
re-learn how to stand and walk after a stroke or spinal cord injury. We want
the EksoGT systems to be widely accessible to people who never thought they
could walk or stand up again,” commented Ms. Lim
Chwee Foon, President, Asia Pacific, Ekso Bionics. “This will serve as a solid
platform for our growth in Asia.”

 

With Ekso Bionics’ recent expansion plan in
Asia Pacific, EksoGTs are now deployed in Singapore, Hong Kong, and Australia. To
date, EksoGT has helped patients take more than 100 million steps in over 260 rehabilitation
institutions around the world.

About EksoGT

EksoGT is the first exoskeleton cleared by the
FDA for use with stroke and spinal cord injuries from L5 to C7. In Europe, the
CE-Mark cleared EksoGT allows us to work with patients impacted by all
neurological conditions and lower limb weakness. The EksoGT with SmartAssist
software is the only exoskeleton available for rehabilitation institutions that
can provide adaptive amounts of power to either side of a patient’s body,
challenging the patient as they progress through their continuum of care. The
suit’s patented technology provides the ability to mobilize patients earlier,
more frequently, and with a greater number of high intensity steps. To date, this
device has helped patients take 100 million steps in over 260 rehabilitation
institutions around the world.

About Ekso Bionics®

Ekso Bionics^® is a leading
developer of exoskeleton solutions that amplify human potential by supporting
or enhancing strength, endurance and mobility across medical and industrial
applications. Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge, innovative
wearable robots available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with paralysis to
stand up and walk, to enhancing human capabilities on job sites across the
globe. The company is headquartered in the Bay Area and is listed on the Nasdaq
Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding (i) the plans
and objectives of management for future operations, including plans or
objectives relating to the design, development and commercialization of human
exoskeletons, including the iMOVE program and study results, (ii) estimates,
projections or other future statements regarding financial performance, results
and condition, capital expenditures, capital structure or other financial items,
including statements relating to growth in Asia, and (iii) the assumptions
underlying or relating to any statement described in points (i) or (ii) above.
Such forward-looking statements are not meant to predict or guarantee actual
results, performance, events or circumstances and may not be realized because
they are based upon the Company’s current projections, plans, objectives,
beliefs, expectations, estimates and assumptions and are subject to a number of
risks and uncertainties and other influences, many of which the Company has no
control over. Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking statements as
a result of these risks and uncertainties. Factors that may influence or
contribute to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may include,
without limitation, the Company’s inability to obtain adequate financing to
fund the Company’s operations and necessary to develop or enhance our
technology, the significant length of time and resources associated with the
development of the Company’s products, the Company’s failure to achieve broad
market acceptance of the Company’s products, the failure of our sales and
marketing organization or partners to market our products effectively, adverse
results in future clinical studies of the Company’s medical device products,
the failure to obtain or maintain patent protection for the Company’s
technology, failure to obtain or maintain regulatory approval to market the
Company’s medical devices, lack of product diversification, existing or
increased competition, and the Company’s failure to implement the Company’s
business plans or strategies. These and other factors are identified and
described in more detail in the Company’s filings with the SEC. To learn more
about Ekso Bionics please visit us at www.eksobionics.com. The Company does not
undertake to update these forward-looking statements.